Janssen Pharmaceuticals Inc.'s results of its XARELTO Phase 3b PIONEER AF-PCI clinical trial and new research involving INVOKANA will be featured in presentations at the American Heart Association Scientific Sessions, being held through Wednesday in New Orleans.
PIONEER AF-PCI is the first clinical trial to assess whether or not a non-vitamin K antagonist oral anticoagulant uch as Xarelto could produce a better safety profile in patients who have non-valvular atrial fibrillation who are receiving simultaneous antiplatelet therapy after PCI with stenting compared to warfarin.
"Janssen aims to improve the lives of the millions of people with cardiovascular disease and diabetes by bringing patients transformational care and innovative treatment options," Janssen Vice President of Medical Affairs Dr. Paul Burton said. "This important line-up of late-breaking, clinical and real-world research will reveal new insights with the potential to challenge the current standard of care."
Other presentations scheduled to take place at the American Heart Association's Scientific Sessions will include the revealing of new real-world research that assessed XARELTO’s persistence and adherence levels and topline results from the Premier Healthcare Database analysis assessing the frequency people use oral anticoagulants with NVAF.